REGN vs REPX · P/E 14, rev $14.34B vs P/E 12, rev $410.2M
Regeneron Pharmaceuticals Inc (REGN) versus Riley Exploration Permian Inc (REPX) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Riley Exploration Permian Inc (REPX) is a oil & gas e&p company listed on AMEX.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported REPX revenue for 2024-12-31 was $410.2M. Net income was $88.9M. Revenue was up 9.4% from 2023-12-31 to 2024-12-31. REPX currently screens at market cap $727.0M and trailing P/E 11.7.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. REPX currently screens at market cap $727.0M and trailing P/E 11.7.
Not investment advice. Open the REGN and REPX stock pages for the full models.
Not investment advice.